<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Aptevo Therapeutics Inc.

    verified_userVerify Profile
    Companies » Health Care » Health Care Equipment & Services » Biotechnology

    About Aptevo Therapeutics Inc.

    Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Aptevo has a commercial product, IXINITY® coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology – the ADAPTIR™ modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer and autoimmune diseases. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Marvin L. White
    • FOUNDED
      2016
    • EMPLOYEES
      101-250
    • SECTOR
      Health Care Equipment & Services
    • SUBSECTOR
      Biotechnology

    Company Tags

    No articles found.

    Supernus Pharmaceuticals, Inc.

    Supernus Pharmaceuticals, Inc.

    Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing a...

    Supernus Pharmaceuticals, Inc. is a pharmaceuti...

    Filing Type:    PU
    Onconova Therapeutics, Inc.

    Onconova Therapeutics, Inc.

    Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused o...

    Onconova Therapeutics, Inc. is a Phase 3-stage ...

    Filing Type:    PU
    Ansell Ltd.

    Ansell Ltd.

    Ansell Limited provides health and safety protection solutions. The Company has op...

    Ansell Limited provides health and safety prote...

    Filing Type:    PR
    BioSig Technologies, Inc.

    BioSig Technologies, Inc.

    BioSig Technologies is a medical device company developing a proprietary technolog...

    BioSig Technologies is a medical device company...

    Filing Type:    PU
    Oracle Health, Inc.

    Oracle Health, Inc.

    Oracle Health is developing a Digital Health Insertable (Under The Skin) Cardiac D...

    Oracle Health is developing a Digital Health In...

    Amount Raised:    $182,002.00
    Fundraising Status:    EC
    Filing Type:    CF
    Halo Cures, Inc.

    Halo Cures, Inc.

    Halo gives scientists and academics opportunities to connect with industry partner...

    Halo gives scientists and academics opportuniti...

    Filing Type:    CF
    Immuron Limited

    Immuron Limited

    Immuron Ltd is a publicly listed Australian biopharmaceutical company focused on o...

    Immuron Ltd is a publicly listed Australian bio...

    Filing Type:    PU
    Immutep Limited

    Immutep Limited

    We are a biotechnology company developing novel immunotherapy treatments for cance...

    We are a biotechnology company developing novel...

    Filing Type:    PU
    Mustang Bio, Inc.

    Mustang Bio, Inc.

    Mustang Bio, Inc. (“Mustang”), a Fortress Biotech Company, is a clinical-stage...

    Mustang Bio, Inc. (“Mustang”), a Fortress B...

    Filing Type:    PU
    Cyclacel Pharmaceuticals, Inc.

    Cyclacel Pharmaceuticals, Inc.

    Cyclacel's founding scientist, Professor Sir David Lane, a globally recognized aut...

    Cyclacel's founding scientist, Professor Sir Da...

    Filing Type:    PU
    Cleveland BioLabs, Inc.

    Cleveland BioLabs, Inc.

    Cleveland BioLabs, Inc. (NASDAQ: CBLI) is an innovative biopharmaceutical company ...

    Cleveland BioLabs, Inc. (NASDAQ: CBLI) is an in...

    Filing Type:    PU
    INmune Bio Inc.

    INmune Bio Inc.

    INmune Bio Inc. is a clinical stage biotechnology company that is developing new i...

    INmune Bio Inc. is a clinical stage biotechnolo...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.